What is the role of mannitol or tobramycin in the treatment of cystic fibrosis (CF)?

Updated: Oct 22, 2019
  • Author: Girish D Sharma, MD, FCCP, FAAP; Chief Editor: Kenan Haver, MD  more...
  • Print

A 2012 study exploring new treatment strategies for CF assessed whether long-term treatment with inhaled mannitol improves lung function and morbidity. Results showed that adding inhaled dry powder mannitol to standard therapy for CF produced sustained improvement in lung function for up to 52 weeks. [78]

In March 2013, the FDA approved tobramycin inhalation powder for the treatment of CF patients with P aeruginosa. [79] The powder is inhaled twice daily for 28 days; treatment is then stopped for 28 days before resuming. In a study of 95 pediatric and adult CF patients infected with P aeruginosa, those treated with inhaled tobramycin powder experienced a significant increase in forced expiratory volume in 1 second (FEV1) compared with placebo-treated patients (12.5% vs 0.09%).

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!